- Home
- CACC vs RNA Comparison
CACC vs RNA Comparison
Compare CACC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CACC | RNA |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 1992 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CACC | RNA |
|---|---|---|
| Price | $460.74 | $71.32 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $465.00 | $69.26 |
| AVG Volume (30 Days) | 103.2K | ★ 2.7M |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.44 | N/A |
| EPS | ★ 37.89 | N/A |
| Revenue | ★ $1,232,900,000.00 | $20,868,000.00 |
| Revenue This Year | $129.15 | $64.11 |
| Revenue Next Year | $1.97 | $37.25 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | 45.72 | ★ 106.27 |
| 52 Week Low | $401.90 | $21.51 |
| 52 Week High | $560.00 | $71.79 |
Technical Indicators
Market Signals| Indicator | CACC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 73.44 |
| Support Level | $448.94 | $71.18 |
| Resistance Level | $474.68 | $71.79 |
| Average True Range (ATR) | 14.60 | 0.41 |
| MACD | 4.08 | -0.73 |
| Stochastic Oscillator | 78.23 | 65.69 |
Price Performance
Historical ComparisonAbout CACC Credit Acceptance Corporation
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.